C4 Therapeutics Reports Q2 2026 Financial Results

What Happened
On August 11, 2026, C4 Therapeutics, Inc. (NASDAQ: CCCC) announced it issued a press release reporting its financial results and business highlights for the quarter ended June 30, 2026. The press release was furnished as Exhibit 99.1 to a Current Report on Form 8‑K (filed August 11, 2026) under Item 2.02 (Results of Operations and Financial Condition). The filing was signed by Kendra R. Adams, Chief Financial Officer.

Key Details

• Filing date: August 11, 2026; Item reported: 2.02 (Results of Operations and Financial Condition).
• Period covered: quarter ended June 30, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8‑K; Inline XBRL cover page included as Exhibit 104.
• Signed by Kendra R. Adams, CFO, Head of Corporate Affairs, and Treasurer. The 8‑K text itself does not include detailed financial figures — those appear in the furnished press release.

Why It Matters
This 8‑K is the company’s official disclosure that its latest quarterly earnings and business updates are available. Retail investors should review the furnished press release (Exhibit 99.1) to see reported earnings, revenue, cash position, guidance (if provided), and program updates, and watch for any follow‑up filings or an earnings call for full financial statements and analyst commentary.